Nevertheless, although our study was limited in exploring all the pathways involved in the pathogenesis of AD, it is significant that CBC attenuated the inflammatory response by inhibiting Th2 cytokines (IL-4 and IL-13) and modulating the JAK/STAT pathway, which are currently major therapeutic targets, and could be a potential treatment option to replace or complement conventional steroids or immunosuppressants. The gene discussed is IL13; the disease is Alzheimer disease.